本季度信息
美因基因公布2025年上半年财务数据，营收人民币0.81亿元，同比下降24.2%。经调整净利润人民币0.27亿元，同比下降26.3%。管理层将营收下滑主要归因为销售策略调整，短期内收入减少叠加房租、人工及折旧等相对固定成本所致。
毛利率为74.0%，同比上升9.1个百分点。期内经营活动现金流由上年同期的人民币1497.3万元转为本期的-129.3万元。销售及分销开支同比下降23.4%，行政开支同比上升2.7%，研发投入同比减少约18.0%。
业务分项
消费级基因检测的服务及配套实现收入人民币0.76亿元，同比下降27.3%。癌症筛查的服务及配套录得人民币0.05亿元收入，同比大幅增长85.7%。管理层指出，癌症筛查方面的产品类别不断丰富，带动了该板块收入的快速攀升，但由于销售策略调整对整体业务构成影响，消费级检测板块阶段性回落。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.